Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.
The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...
Its innovative medicines division climbed 15% to $10.6 billion on continued strong growth for immunology blockbuster Cosentyx (secukinumab) and heart failure therapy Entresto (sacubitril/valsartan ...
The performance of Zolgensma came alongside some impressive results for some of Novartis’ other key drugs, including Cosentyx (secukinumab) for psoriasis which grew 27% to $937 million in the ...
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three ...
secukinumab, tocilizumab, ustekinumab Increased risk of serious infections, increased risk of some cancers DMARD = disease-modifying antirheumatic drug; TNF = tumor necrosis factor. Glucocorticoids ...
Shareholders approved 28th consecutive dividend increase to CHF 3.50 (+6.1%) per share for 2024, representing a 3.5% yield¹ Shareholders elected Giovanni Caforio as new member and Chair of the ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback